These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 19937937)

  • 21. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital.
    Zou Z; Ma L; Li H
    J Magn Reson Imaging; 2009 Dec; 30(6):1309-12. PubMed ID: 19937931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.
    Gauthier ID; Macleod CA; Sathiadoss P; McGrath TA; Nair V; Schieda N
    Abdom Radiol (NY); 2022 Mar; 47(3):1196-1201. PubMed ID: 34997298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.
    Alhadad A; Sterner G; Svensson Å; Alhadad H; Leander P
    Scand J Urol Nephrol; 2012 Feb; 46(1):48-53. PubMed ID: 22008005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.
    McWilliams RG; Frabizzio JV; De Backer AI; Grinberg A; Maes BD; Zobel BB; Gottschalk A
    J Magn Reson Imaging; 2020 Feb; 51(2):607-614. PubMed ID: 31287213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
    Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
    AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.
    Starekova J; Bruce RJ; Sadowski EA; Reeder SB
    Radiology; 2020 Dec; 297(3):556-562. PubMed ID: 32990511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.
    Wertman R; Altun E; Martin DR; Mitchell DG; Leyendecker JR; O'Malley RB; Parsons DJ; Fuller ER; Semelka RC
    Radiology; 2008 Sep; 248(3):799-806. PubMed ID: 18632533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nephrogenic systemic fibrosis.
    Vosshenrich R; Reimer P
    Vasa; 2009 Feb; 38(1):31-8. PubMed ID: 19229801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
    Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol CB; Hiremath S
    Can J Kidney Health Dis; 2018; 5():2054358118778573. PubMed ID: 29977584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana.
    Piersson AD; Gorleku PN
    Radiography (Lond); 2017 Nov; 23(4):e108-e113. PubMed ID: 28965904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nephrogenic systemic fibrosis: clinical spectrum of disease.
    Mayr M; Burkhalter F; Bongartz G
    J Magn Reson Imaging; 2009 Dec; 30(6):1289-97. PubMed ID: 19937929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.
    Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL
    J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
    Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
    Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of nephrogenic systemic fibrosis in liver transplantation patients.
    Chow DS; Bahrami S; Raman SS; Rotchel S; Sayre JW; Busuttil RW; Lu DS
    AJR Am J Roentgenol; 2011 Sep; 197(3):658-62. PubMed ID: 21862808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS; Sheller A
    Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols.
    Martin DR; Krishnamoorthy SK; Kalb B; Salman KN; Sharma P; Carew JD; Martin PA; Chapman AB; Ray GL; Larsen CP; Pearson TC
    J Magn Reson Imaging; 2010 Feb; 31(2):440-6. PubMed ID: 20099361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
    Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol C; Hiremath S
    Can Assoc Radiol J; 2018 May; 69(2):136-150. PubMed ID: 29706252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
    Bryant BJ; Im K; Broome DR
    Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.